|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||
| Deferred offering costs | ||||||||||
| Cash | ||||||||||
| Prepaid expenses | ||||||||||
| Income tax receivable | ||||||||||
| Total current assets | ||||||||||
| Non-current prepaid insurance | ||||||||||
| Marketable securities held in Trust Account | ||||||||||
| TOTAL ASSETS | ||||||||||
| Current liabilities | ||||||||||
| Accrued expenses | ||||||||||
| Accrued offering costs | ||||||||||
| Income tax payable | ||||||||||
| Total current liabilities | ||||||||||
| Warrant liabilities | ||||||||||
| Deferred tax liability | ||||||||||
| Excise tax payable | ||||||||||
| Deferred underwriting fee payable | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Class A common stock subject to possible redemption; 1,475,493 and 15,761,850 shares at redemption value at September 30, 2023 and December 31, 2022, respectively | ||||||||||
| STOCKHOLDERS’ DEFICIT | ||||||||||
| Common stock, value | ||||||||||
| Class A Common Stock | ||||||||||
| Class B Common Stock | ||||||||||
| Total common stock, value | ||||||||||
| Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 4,312,500 shares issued and outstanding (1) | ||||||||||
| Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 3,940,462 shares issued and outstanding at March 31, 2023 and December 31, 2022 | ||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated deficit | ||||||||||
| TOTAL STOCKHOLDERS’ DEFICIT | ||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
Loading...